Committed to creating a world without diabetes
Our vision at The Ohio State University Wexner Medical Center’s Diabetes and Metabolism Research Center is “to create a world without diabetes.” Our dedicated team of physicians and researchers are committed to making this vision a reality by focusing on personalized health care to provide better outcomes in research, patient care and education.
The Diabetes and Metabolism Research Center is committed to conducting clinical trials and basic research that translate to managing, preventing and curing diabetes. Our patients have access to participate in state-of-the-art clinical trials for new drugs and technologies.
The Diabetes and Metabolism Research Center collaborates with several divisions to foster a team approach in innovative procedures such as islet cell, pancreas and kidney transplantation. In 2008, The Ohio State University Wexner Medical Center conducted the first human islet cell transplant in Ohio, and is one of few centers in the nation to offer this new and innovative treatment option.
Research conducted at the center
Islet Cell Research
The ability to perform ICT at Ohio State epitomizes advancement in the care of patients with severe beta cell pancreatic diseases. The ICT program in both human and non-human primates has been a joint venture between Ohio State's Diabetes and Metabolism Research Center and Comprehensive Transplantation Center. Dr. Wang, a researcher within the Division of Endocrinology, Diabetes and Metabolism and the Diabetes and Metabolism Research Center, set up an entire lab devoted to the basic research of islet cell biology. The lab is wholly focused on clinical research in the related field of diabetes study, which Dr. Wang had initially started at the HHMI lab in the University of Chicago in November 2006.
Improving beta cell function in young Mexican American women with prediabetes
This R01-funded investigation, led by principal investigator Willa Hsueh, MD, targets serious health disparities in metabolic disease in a highly vulnerable, rapidly growing population. It tests novel gender- and culturally-focused intervention strategies lead by co-investigator Evangelina Villagomez, PhD, in Houston, TX. The study team includes, Kathleen Wyne, MD, PhD, and David Bradley, MD. The primary endpoint will be improved pancreatic function Beta (β)-cell function (acute insulin response, deposition index) defined by frequently sampled intravenous glucose tolerance testing. Secondary endpoints include changes in β-cell markers (C-peptide, insulinogenic index (IGI), glucagon), novel plasma biomarkers that predict diabetes and inflammation and metabolic syndrome components.
Most genes that have been identified for diabetes-related traits influence β-cell growth, differentiation and function. Co-investigators from UCLA, Drs. Rotter, Chen and Goodarzi, will assist this team in selecting a group of single nucleotide polymorphisms (SNPs) on the Metabochip to correlate variations in such type 2 diabetes genes and loci with insulin responses and other phenotypes in liraglutide-treated subjects.
Our objective is to combine an intensive lifestyle intervention approach (LSI), in combination with a glucagon-like peptide-1 agonist to improve β-cell function and prevent the downward spiral of metabolic disease in the Mexican American community plagued by poverty. We are targeting Mexican American women because they have the highest rates of metabolic syndrome in the U.S. compared to men or other ethnic groups.
Recent large multicenter inpatient and outpatient studies have highlighted the potential benefits as well as potential dangers of tight blood sugar control. Such studies have prompted calls for safer, more individualized approaches to diabetes therapy, particularly in patients with end organ complications. In particular, measures to stabilize glucose fluctuations may have the potential to preserve or enhance the benefits of glycemic control while reducing the risks for hypoglycemia. Several preliminary studies indicate that extreme fluctuations in glucose (glucose variability) are associated with cellular dysfunction, heart rhythm abnormalities and death, even if more conventional assessments of “average” glucose are acceptable.
Research initiatives include retrospective analysis of quality control measures as well as prospective studies, including the study of optimal methods of implementing insulin therapy in the hospital setting and the utility of continuous subcutaneous glucose monitoring technology.
Ongoing clinical research trials
The Division of Endocrinology, Diabetes and Metabolism and the DMRC are currently enrolling in the following clinical trials. Each study has specific requirements for enrollment.
HPP 501 Registry
Please contact Ashley Mintos at 614-688-6885 if interested.
A phase three clinical trial for patients diagnosed with nonalcoholic steatohepatitis (NASH).
Please contact Amber Anaya at 614-688-6257 should you be interested in participating.
Requirements for enrollment:
- Immediate family ages one to 45, including siblings, mother, father, child OR
- Nieces, nephews, aunts, uncles and grandchildren ages one to 20
If interested please call Angela Howell at 614-688-6258.